We have previously demonstrated systemic delivery of lipid-protamine-RNA nanoparticles encapsulating mRNA encoding a ZF protein upregulating the MASPIN promoter for the treatment of serous ovarian cancer.38 Such lipid-protamine-RNA technology could be similarly adapted to deliver the ZF-DNMT3A constructs for stable heterochromatization of SOX2. The small, compact molecular architecture of ZF domains and their lack of immunogenicity make them very suitable molecular scaffolds for this type of delivery. This evidence concerns the gene DNMT3A and ovarian serous adenocarcinoma.